New Company to Make Combination Drugs
Posted on: Thursday, 1 February 2007, 21:00 CST
A Chicago-area pharmaceutical entrepreneur has launched a company to develop combination medicines that treat multiple ailments with one pill.
Brian Tambi, who once turned around a generic drug maker, has formed BrianT Laboratories in Lake Forest, Ill., to develop branded drugs that combine cholesterol medications with hypertension drugs.
Plans call for the company eventually to develop a portfolio of combination drugs.
Combination pills are more convenient and address multiple consumer-health issues, particularly aging baby boomers, analysts say.
The company believes the drugs will protect brand-name drug makers' share of lucrative franchises, the Chicago Tribune reports.
The global cholesterol market alone is estimated at more than $30 billion.
Major drug makers such as Pfizer Inc., Merck & Co. and Abbott Laboratories are already developing combination superpills to treat a variety of conditions.
Tambi says combination pills can be developed for a fraction of the time and cost of original drugs -- about four years for combination pills compared with 12 for the original.
You do not have to do the long, drawn-out trials ... because a lot of the safety data is already in the public domain, Tambi said.
Source: United Press International
Related Articles
- Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
- An Obesity Drug Pipeline Report: The Development of Therapies for a Complex Disease
- Advances In Drug Discovery Technologies Fuelling Development of Anti-Diabetic Therapies
- New Drugs, New Drug Targets Make Prospects Brighter for Flu Drug Pipeline
- Over Half of Physicians Prefer Two Drugs in a Single Pill Combination for the Treatment of Cardiovascular Disease
- eRx Collaborative Boosts Patient Safety With 8,000 Prescriptions Changed in June; Record Number of Electronic Prescriptions Changed As a Result of Drug-Drug and Drug-Allergy Alerts
- Intec Pharma Collaborates With BioEnvelop and Tapemark - Gears Up Large-Scale Manufacturing of SuperGeneric Drugs Using Accordion Pill(TM) Gastric Retention Technology
- Report Series Uncovers the Commercial Outlook for Currently Marketed Drugs and Drugs in Research and Development
- Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs
- Kinex Pharmaceuticals Selects Lead Drug Candidate for Clinical Development in Oncology
 |
 |
User Comments (0)
RSS Feeds